INCY vs. SNY: Incyte vs. Sanofi Stock Comparison

Company Profile

Incyte (INCY) and Sanofi (SNY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but INCY is classified in Biotechnology while SNY is classified in Pharmaceuticals.

Incyte (INCY) trades as ordinary local shares, while Sanofi (SNY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Incyte (INCY) at 7.84% sits in the top ROE quartile, while Sanofi (SNY) at 5.72% is closer to the peer norm — stronger capital efficiency for INCY.

For every dollar of sales, both Incyte (INCY) at 6.71% and Sanofi (SNY) at 8.20% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

Both Incyte (INCY) at 33.72% and Sanofi (SNY) at 30.89% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Incyte (INCY) at 21.22% and Sanofi (SNY) at 5.49% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Incyte (INCY) at 4,173.33% clears its industry range for EPS growth, a much stronger earnings trajectory than Sanofi (SNY) at 39.43%, which is closer to a typical peer reading.

Growth Metrics

Financial Strength

Incyte (INCY) at 3.84 keeps current ratio within its industry’s typical mid-range, while Sanofi (SNY) at 1.12 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for SNY.

Incyte (INCY) at 0.01 keeps leverage in the lower industry quartile, while Sanofi (SNY) at 0.27 runs a more typical debt-to-equity mix.

Financial Strength Metrics

Dividends

Neither Incyte (INCY) nor Sanofi (SNY) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Sanofi (SNY) reports payout ratio above 100% at 119.86%, meaning dividends exceeded current-period earnings; Incyte (INCY) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

Sanofi (SNY) at 23.40 is near its industry’s usual P/E ratio, while Incyte (INCY) at 61.05 sits in the richer quartile — INCY needs stronger growth or earnings quality to justify the premium.

Sanofi (SNY) at 2.21 sits in the cheaper P/S ratio quartile while Incyte (INCY) at 4.06 prices around its industry’s middle — SNY costs less per dollar of sales, though read it alongside growth and margins.

Sanofi (SNY) at 1.38 sits in the lower P/B ratio quartile against book while Incyte (INCY) at 4.33 is valued near its industry’s middle — SNY is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics